A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 10, 2012, Pages 2342-2349

  Barbazán, Jorge ^a   Vieito, María ^a   Abalo, Alicia ^a   Alonso Alconada, Lorena ^a   Muinelo Romay, Laura ^a   Alonso Nocelo, Marta ^a   León, Luís ^a   Candamio, Sonia ^a   Gallardo, Elena ^a   Anido, Urbano ^a   Doll, Andreas ^b   de los Ángeles Casares, María ^c   Gómez Tato, Antonio ^c   Abal, Miguel ^a   López López, Rafael ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Biomarkers; CD45; Circulating tumour cells; GAPDH; Logistic model; Metastatic colorectal cancer; VIL1

Indexed keywords

ACTIN BINDING PROTEIN; CD45 ANTIGEN; PTPRC PROTEIN, HUMAN; TUMOR MARKER; VILLIN1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; EPITHELIUM CELL; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84863712510     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01544.x     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-49.
2. Negin BP, Cohen SJ. Circulating tumour cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol. 2010; 11: 1-13.
3. Cohen SJ, Punt CJ, Iannotti N, et al. Prognostic significance of circulating tumour cells in patients with metastatic colorectal cancer. Ann Oncol. 2009; 20: 1223-9.
4. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumour cells to tumour response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 3213-21.
5. Garrigos N, Gallego J, Guillen-Ponce C, et al. Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. Clin Transl Oncol. 2010; 12: 142-7.
6. Allen JE, El-Deiry WS. Circulating tumour cells and colorectal cancer. Curr Colorectal Cancer Rep. 2010; 6: 212-20.
7. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-47.
8. Wong SC, Chan CM, Ma BB, et al. Clinical significance of cytokeratin 20-positive circulating tumour cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res. 2009; 15: 1005-12.
9. Rigau M, Morote J, Mir MC, et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate. 2010; 70: 1760-7.
10. Sieuwerts AM, Kraan J, Bolt-de Vries J, et al. Molecular characterization of circulating tumour cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat. 2009; 118: 455-68.
11. Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010; 16: 398-406.
12. Konigsberg R, Gneist M, Jahn-Kuch D, et al. Circulating tumour cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett. 2010; 293: 117-23.
13. Lin H, Balic M, Zheng S, et al. Disseminated and circulating tumour cells: Role in effective cancer management. Crit Rev Oncol Hematol. 2010; 77: 1-11.
14. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009; 69: 5627-9.
15. Horst D, Kriegl L, Engel J, et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008; 99: 1285-9.
16. Herrmann I, Baeuerle PA, Friedrich M, et al. Highly efficient elimination of colorectal tumour-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS One. 2010; 5: e13474.
17. Dandachi N, Balic M, Stanzer S, et al. Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients. J Mol Diagn. 2005; 7: 631-7.
18. Maestro LM, Sastre J, Rafael SB, et al. Circulating tumour cells in solid tumour in metastatic and localized stages. Anticancer Res. 2009; 29: 4839-43.
19. Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumour cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010; 138: 1714-26.
20. Wang JY, Lin SR, Wu DC, et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res. 2007; 13: 2406-13.
21. Gazzaniga P, Naso G, Gradilone A, et al. Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumours. Int J Cancer. 2010; 126: 2437-47.
22. Gazzaniga P, Gradilone A, Petracca A, et al. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. J Cell Mol Med. 2010; 14: 2073-7.
23. Tol J, Koopman M, Miller MC, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2010; 21: 1006-12.